Compared with trastuzumab, despite their similar macromolecular property and drug tissue distribution, T-DM1 led to the delayed growth of HER2-positive brain tumors and increased tumor-cell apoptosis in mouse models [51], which could explain the efficacy of T-DM1 in BCBM to some extent. This evidence concerns the gene ERBB2 and neoplasm.